Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
dimanche, octobre 25
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Kyverna Therapeutics Inc
KYTX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$5.39
-0.34
-5.93%
Dern. MÀJ: Oct 23, 6:48 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Kyverna Therapeutics Financials
Kyverna Therapeutics (KYTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.68) by 7.35 percent. This is a 35.05 percent increase over losses of $(0.97) per share
Benzinga Newsdesk
PRO
Kyverna Therapeutics Q1 EPS $(0.66) Beats $(0.73) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.73) by 9.59 percent. This is a 35.92 percent increase over losses of $(1.03) per share
Benzinga Newsdesk
Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving?
Kyverna Therapeutics Inc. shares surged 24% after hours following positive registrational trial results for miv-cel in stiff person syndrome, showing significant improvement in walking speed.
Mohd Haider
PRO
Kyverna Therapeutics Q4 EPS $(0.80) Beats $(0.85) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.85) by 5.66 percent. This is a 8.11 percent decrease over losses of $(0.74) per share
Benzinga Newsdesk
Crude Oil Rises Over 1%; General Mills Earnings Top Views
Avi Kapoor
Dow Jumps 150 Points; Jabil Posts Upbeat Earnings
Avi Kapoor
